Reversing the Effect of Oral Anticoagulant Drugs: Established and Newer Options
Author:
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Cardiology and Cardiovascular Medicine,General Medicine
Link
http://link.springer.com/content/pdf/10.1007/s40256-016-0162-7.pdf
Reference58 articles.
1. Guyatt GH, Akl EA, Crowther M, Gutterman DD, Schuunemann HJ, for the American College of Chest Physicians Antithrombotic Therapy and Prevention of Thrombosis Panel. Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141(No. 2 Suppl):e1S–e801S.
2. Budnitz DS, Lovegrove MC, Shehab N, Richards CL. Emergency hospitalizations for adverse drug events in older Americans. N Eng J Med. 2011;365:2002–12.
3. Budnitz DS, Shehab N, Kegler SR, Richards CL. Medication use leading to emergency department visits for adverse drug events in older adults. Ann Intern Med. 2007;147:755–65.
4. Shepherd G, Mohorn P, Yacoub K, May DW. Adverse drug reaction deaths reported in United States Vital Statistics, 1999–2006. Ann Pharmacother. 2012;46:169–75.
5. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. The pharmacology and management of the vitamin K antagonists: ACCP evidence-based clinical practice guidelines. Chest. 2008;133:160S–98S.
Cited by 17 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Anticoagulant Activity of Hybrid Molecules Based on 2,2,4-Trimethyl-4-aryl-1,2,3,4-tetrahydroquinoline and Nitrogen-Containing Heterocycles;Russian Journal of General Chemistry;2023-12
2. Synthesis, Docking, and In Vitro Anticoagulant Activity Assay of Hybrid Derivatives of Pyrrolo[3,2,1-ij]Quinolin-2(1H)-one as New Inhibitors of Factor Xa and Factor XIa;Molecules;2020-04-19
3. Andexanet alfa in the treatment of acute major bleeding related to apixaban and rivaroxaban: a profile of its use in the USA;Drugs & Therapy Perspectives;2018-10-05
4. Advances in the Development of Novel Factor Xa Inhibitors: A Patent Review;Mini-Reviews in Medicinal Chemistry;2018-09-13
5. Andexanet Alfa: First Global Approval;Drugs;2018-06-20
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3